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Abstract 
Apoptin, Chicken Anemia Virus VP3, selectively induces apoptosis in transformed cells but not primary 
cells. In all cases, Apoptin undergoes nucleocytoplasmic shuttling, but partitions into the nucleus of 
transformed cells and the cytoplasm of primary cells. The N-terminal NES of Apoptin and the domain for 
multimerization overlap and all previous attempts to uncouple these activities have failed. In this study, 
we successfully uncoupled nuclear export and multimerization through site-directed mutagenesis of 
ApI37A and ApI40A. Uncoupling these activities and studying them independently could shed insight 
into basic biochemical differences between transformed and primary cells that could be exploited for 
targeted therapeutic purposes. 
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Introduction 
The Chicken Anemia Virus (CAV) 
 The chicken anemia virus was discovered to be an avian pathogen that causes the eradication of 
thymocytes and erythroblastoid cells in chicks through the induction of apoptosis ( 1).It resembles the 
porcine circovirus (PCV) and is a member of the family Circoviridae and the genus Gyroviridae. It is a 
circular, single stranded DNA composed of approximately 2300 nucleotides that has 3 open reading 
frames (ORFs) which all partially overlap: VP1, VP2, and VP3 ( 2,3). ORF 3 encodes the 51 kDa protein 
VP1 which responsible for the assembly of the viral capsid. ORF1 encodes the 28 kDa protein, VP2, a 
non-structural protein with dual specifity phosphatase (DSP) activity. It has a very unusual signature 
motif that may play a role in intracellular signaling during viral replication and is the first DSP to be 
identified in a small viral genome ( 4). VP2 is expressed at barely detectable levels during infection ( 5,4).  
Lastly, ORF2 encodes the 13 kDa protein, VP3, also known as Apoptin ( 5). In many studies, it is shown 
that Apoptin selectively induces apoptosis in chicken and human tumor cells and not in most normal 
cells through a p53 independent pathway ( 1,6,7). CAV’s VP3 alone is necessary and sufficient to induce 
apoptosis and discriminate between cancerous and normal cells. 
CAV VP3: Apoptin 
 The VP3 of CAV (Apoptin) is composed of 121 amino acids with two proline rich regions and two 
basic regions. It overlaps with CAV VP2 ( 7) and has no discernable regular structure ( 8). Using circular 
dichroism (CD), Leliveld and coworkers determined that Apoptin was “nearly devoid of an alpha-helical 
structure” and that the CD spectrum of Apoptin resembled other proteins with an unordered structure ( 
8).   
 Apoptin has a bipartite basic nuclear localization sequence (NLS) located at the C-terminus of 
the protein between amino acids 80-121 ( 1,2,9). To determine whether the bipartite NLS was 
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functional, Heilman and coworkers induced point mutations K86A, K87A, R88A in the first part of the 
bipartite NLS, and K116A, R117A, and R118A in the second part of the bipartite NLS (all on Ap-pmNLS). 
Results show that the mutant Ap-pmNLS mislocated to the cytoplasm of H1299 cells, indicating that the 
bipartite NLS is indeed functional ( 2). 
 Apoptin has a distinct leucine rich nuclear export sequence (LR-NES) located at the N-terminus 
of the protein between amino acids 33-46 ( 2). There have been many different studies done to 
determine the correct NES for Apoptin. The NES was believed to be between amino acids 97 through 
105 and that amino acids 33 through 46 contained a leucine rich sequence (LRS) that facilitates nuclear 
import ( 10,11). However, this was disproved by Heilman et al., (2006) by inducing point mutations L44A 
and L46A on GFP-Ap-pmNES which actually mislocated to the nucleus in PFF (primary foreskin 
fibroblasts) cells showing that the NES (aa 33-46) is functional ( 2). In addition, they also showed that the 
putative N-terminus NES was CRM1-dependent which further indicates that the N-terminus NES is 
functional ( 2). The NES of Apoptin (IRIGIAGITITLSL) resembles the NES of Rev- or PKIα-. The canonical 
sequence for NESs is Φ(X)2-3Φ(X)2-3ΦXΦ, where Φ represents hydrophobic amino acids (Lys, Val, Ile, Phe, 
or Met) and X is any amino acid ( 12). Apoptin’s NES fits the canonical sequence from I37 to L46 
(IAGITITLSL), while the rest of the N-terminal domain I33 through G36 (IRIG) are part of the NES, but do 
not fit the canonical sequence for NES.  
 
Nuclear Export: LR-NESs and CRM1 
Leucine rich nuclear export signals (LR-NESs) typically contain alternating hydrophobic residues 
that fit the canonical NES and are additionally rich in acidic amino acids, which makes them more 
negatively charged ( 13). They are also either flexible themselves or near very flexible regions and tend 
to be in an alpha helix conformation at least at the N-terminal end of the NES (although there are small 
percentages of NESs in a coil or beta sheet conformation) ( 12,13).  Alpha-helical NESs also have a clear 
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tendency to have the majority of their hydrophobic residues on one side of the helix, the side which 
makes contact with their exportin, typically CRM1. La Cour et al. (2004) analyzed the structures of six 
NESs in an alpha helix conformation and noticed that the structure of the N-terminal hydrophobic 
residues of NESs tend to stack together on one side of the helix and on the C-terminal end of the NES, 
the hydrophobic amino acids bend off differently. Their data is not completely representative of all 
NESs, but are just shown to illustrate a commonality between a large percentage of NESs in alpha helix 
conformation ( 13).  
The interaction surface of CRM1, the exportin protein that binds to LR-NESs, is a hydrophobic 
groove formed by 3 helices (H11A, H11B, and H12A) that is structured as follows: Two helices (H11A and 
H12A) parallel to each other spaced farther apart at the end that bind the N-terminal end of NESs which 
gradually narrows to a bottle neck towards the C-terminal end of the NES.  Past the bottleneck of the 
hydrophobic pocket that binds the C-terminal end of NESs is a narrow channel.  H11B is underneath 
both H11A and H12A and additionally contributes to the hydrophobicity of the groove. Dong and 
coworkers comment on the fact that the hydrophobic pocket of CRM1 where the N-terminus of NESs 
interact with CRM1 is a wider area that besides binding alpha helix NESs, could also accommodate NESs 
in a coil or beta sheet conformation (which illustrates the degeneracy of NESs) ( 12).  
Nuclear Import and Export: Apoptin 
Nuclear import and export is done through nuclear pore complexes (NPCs) with the help of 
karyopherins (kap) (Figure 1). NPCs allow molecules with a mass of 40kDa or less to pass freely through 
their aqueous channel. Any molecule larger than 50kDa can actively pass through with the help of a kap. 
Cleverly, Kaps that mediate import are called importins (IMPs) and kaps that mediate export are called 
exportins ( 11). 
 Apoptin has been shown to be imported into the nucleus via the IMP 1 protein which uses the 
RanGTP cycle. IMP 1 binds to the NLS of Apoptin in the cytoplasm which allows the docking of the VP3 
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to the NPC. The VP3 is then translocated across the NPC and into the nucleus. In the nucleus, RanGTP 
binds to IMP 1 which causes the VP3 to be released ( 11). Exportins, such as CRM1, mediate nuclear 
protein export ( 11,2). CRM1 utilizes the Ran-GTP cycle. RanGTP is bound to CRM1. This complex then 
binds to the NES of Apoptin, docks the protein cargo to the NPC and is transported out of the nucleus 
and into the cytoplasm through the NPC. Once in the cytoplasm, the GTP is hydrolyzed to GDP by Ran 
with the help of Ran GTPase-activating protein, and the Apoptin cargo containing the NES is released 
from the CRM1 ( 11). 
Apoptin: Nuclear and Cytoplasmic Shuttling (NES and NLS) 
Apoptin has a shuttling mechanism that is needed for its apoptotic activity. In transformed cells, 
Apoptin is partitioned in the nucleus prior to apoptosis, while in primary cells, Apoptin is predominantly 
partitioned in the cytoplasm ( 11,2,10). In PFF (Primary Foreskin Fibroblast) cells, Apoptin exhibits a 
filamentous immune-staining pattern in the cytoplasm which suggests that Apoptin might be tightly 
associated with cellular filament networks ( 2)or that it naturally form fibrils. Once Apoptin enters the 
nucleus, it has been shown to bind or enter promyelocytic leukemia (PML) nuclear bodies (NBs) ( 
11,2,10). PML NBs are structured protein bodies that are associated with DNA replication and repair, 
transcription regulation, RNA transport and more interestingly, apoptosis ( 11). Previous studies have 
shown that in tumor cells, Apoptin is phosphorylated at T108 by an unidentified protein kinase while in 
the PML NBs and in primary cells, T108 is not phosphorylated ( 11). However, conflicting results have also 
been demonstrated ( 9). It is also shown that in transformed cells, Apoptin interacts with the APC1 of 
the APC/C through a domain that overlaps with the NLS. Apoptin recruits APC1 to the PML NBs, and 
apoptosis is induced at G2/M. PML bodies are not detectable in the absence of Apoptin and during 
G2/M, PML itself is not heavily present suggesting this is a significant interaction and not artifactual ( 2). 
It is known that Apoptin’s interaction with the APC1 is extremely important because nuclear localization 
in the absence of APC1 association does not induce apoptosis ( 2).  Heilman et al. (2006) also 
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demonstrated that nucleocytoplasmic shuttling of Apoptin is necessary to induce Apoptosis. Inhibition 
of nuclear export by leptomyosin B in cancer cells doesn’t significantly alter Apoptin’s nuclear 
localization, but does eliminate its apoptotic effects. Similarly, artificially stuffing apoptin into the 
nucleus of primary cells with leptomyosin B does not kill the cells ( 2). Despite the important of nucleo-
cytoplasmic shuttling, it is currently unknown how this process is differentially regulated in transformed 
and primary cells. One clue is that Apoptin’s NES appears to be differentially active, while its NLS 
appears constitutive ( 2). One possibility is that shuttling is related to Apoptin’s characteristic ability to 
form large multimers, since its multimerization domain overlaps with the NES. 
Apoptin: Multimerization 
 It has been shown in many different studies that nuclear localization alone is not sufficient for 
efficient apoptosis of normal cells, which suggests that there is another step involved in apoptosis of 
transformed cells ( 6,2,14). Apoptin has a multimerization domain overlapping with the NES (aa 33-46). 
Using secondary structure prediction, Leliveld et al. (2003) determined that amino acids between Glu32 
and Leu46 (the NES of Apoptin) might fold as an anti-parallel beta sheet with Ala38 and Gly39 oriented in a 
beta-turn or -hairpin. If this is the case, since the NES generally has alternating hydrophobic and 
hydrophilic amino acids, the amino acids would be oriented in such a way that the hydrophobic amino 
acids would protrude on one side of the hairpin, and the hydrophilic amino acids would do the opposite. 
They hypothesize that this motif might be responsible for Apoptin’s multimerization properties and 
perhaps the Ile and Leu resides interlock between Apoptin monomers to form the Apoptin multimers ( 
8).  
Apoptin has been shown to be heavily multimerized and insoluble in normal cells, while in 
tumor or transformed cells, it is less multimerized and more soluble. Apoptin spontaneously forms 
multimers composed of approximately 30 to 40 subunits in vitro ( 8). Apoptin’s heavily multimerized 
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state in normal cells along with its proposed association with cellular filament networks might explain 
the difference in solubility and location of Apoptin in normal cells versus transformed cells ( 2). 
Cellular Concentration of Apoptin and Rate of Cellular Division Affects 
Programmed Cell Death 
 A study by Wadia et al. (2004), illustrated that the characteristic ability for Apoptin to localize in 
the nucleus of tumor cells is not the sole mechanism by which apoptosis is induced. They believe that 
programmed cell death (PCD) is dependent on a high cellular concentration of Apoptin to be able to 
form multimers large enough to then localize to the nucleus and induce apoptosis. They transfected ras-
transformed mouse 3T3 cells with increasing amounts of Apoptin DNA and based on scoring of their 
microscopic images, they deduced that increased expression levels of Apoptin in tumor cells lead to 
better nuclear accumulation and finally apoptosis. However, their hypothesis was disproved by Poon et 
al. (2005) who quantitatively analyzed expression levels at the single-cell level rather than assumed 
increased expression levels based on the amount of DNA transfected. Poon and coworkers illustrated 
that there was no relationship between the level of Apoptin expression and the extent of nuclear 
localization in tumor cells. In fact, they were able to conclude from their data that increased levels of 
expression was indirectly proportional to nuclear accumulation in SAOS-2 cells ( 15).  
The rate of cell division has been illustrated to affect Apoptin’s ability to induce apoptosis in 
transformed cell lines. Tumor cells rapidly divide uncontrollably, although different tumor cell lines have 
different rates of replication. Indeed, faster growing tumor cells such as Hela cells which have 
population doubling times (PDT) of 24 hours, were killed within 2 days by Apoptin. Slower growing cells 
such as Saos-2 transformed cells whose PDT is 42 hours, took 5 days for Apoptin to induce apoptosis ( 
16). Evidently, the rate of cellular division plays a role in inducing apoptosis of transformed cells.  
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Besides trying to discern the exact mechanism by which Apoptin induces apoptosis in cancer cell 
lines, even more perplexing is that Apoptin can indeed induce apoptosis in certain non-transformed cells 
(e.g. normal breast epithelial tissue) under certain reaction conditions ( 16). Clearly there is much to be 
discovered about the mechanism by which Apoptin induces apoptosis in different tumor cells versus 
particular non-transformed cell lines. 
  
The Cell Cycle and Cell Cycle Regulators 
The eukaryotic cell cycle is divided into four phases: G1, S, G2 and M. The G1 “gap” phase is the 
longest step in the cell cycle, typically consuming about 18 hours of a typical 24 hour cycle. The G1 
phase is when a cell carries out its “normal” metabolic duties, such as energy metabolism and most 
protein synthesis. If a cell is no longer actively dividing (quiescent), it will enter an indefinite gap phase 
known as G0. Examples of cells in G0 are terminally differentiated muscles cells and neurons. Following 
G1 is the S, or synthesis, phase in which the DNA is replicated. S phase is followed by a smaller gap 
phase, G2, and then the cell proceeds into mitosis in M phase. After the chromosomes have been 
separated into two nuclei, the cell undergoes cytokinesis, yielding two daughters cells and beginning the 
cycle over again. 
 Cells have evolved tight regulation of the cell cycle and have checkpoints that ensure the cell is 
ready to progress to the next stage in the cell cycle. For instance, it would be undesirable for a cell to 
progress to G2 and then M phase before all DNA replication had been completed in S phase. In 
metazoans, cells also retain tight control of the cell cycle to prevent unchecked cell growth, leading to 
cancer. 
 At the heart of cell cycle regulation are the cyclin-dependent kinases (Cdk) which allow for the 
expression of genes needed in the next phase of the cell cycle. Not surprisingly, a Cdk’s activity is 
dependent on the binding of a cyclin, protein’s whose concentrations rise and fall in a cyclic nature with 
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the cell cycle. There are many different cyclins, with each set corresponding to different stages in the 
cell cycle. Once bound by a cyclin, the Cdk enters the nucleus and phosphorylates serine and theronine 
residues on histones. The DNA surrounding the histones changes packing and conformation, allowing for 
the expression of genes needed for the next stage of the cell cycle (Figure 2). Thus Cdks allow for the 
controlled, selective expression of genes that allow the cell cycle to continue to the next stage.  But Cdks 
are also negatively regulated by cyclin depedent kinase inhibitors (CKI). As the name suggests, these 
inhibitors block the function of Cdks and are dependent on the presence of other cyclin proteins. CKI can 
prevent the cell from progressing to the next stage in the cell cycle, and can thus be used by the cell as a 
way of checking against cancer and uncontrolled cell growth. 
Policing the Cell Cycle 
Eukaryotic cells have evolved elaborate mechanics to check uncontrolled cell growth. Perhaps 
the most important cell cycle regulator is the p53/Mdm-2 system. p53 is an antitumor protein that acts 
as a central hub in the cell, being at the cross roads of many different proliferative pathways. If any one 
of these pathways signals that the cell is in danger of becoming cancerous, p53 is activated and arrests 
the cell cycle until the problem is resolved. If the damage is unrepairable, prolonged p53 activation 
commits the cell to apoptosis, killing the cell for the health of the organism. As evidence of p53’s 
effectiveness, half of all cancers have mutated or deleted p53, sidestepping the watchful eye of this 
master cell cycle regulator ( 2,17). In terms of cancer treatment, a mechanism that kills cancer in a p53-
independent manner would be very significant. 
p53 is a transcriptional activator that activates expression of certain CKIs (p21Cip1). Depending on 
the level and duration of expression, the CKI can either lead to a G2 cell cycle arrest or if the signal is 
sustained, CKI expression can commit the cell to apoptosis ( 17). This system gives the cell sometime to 
try to repair the damage that caused the cell cycle arrest. However if the damage is too great, the cell 
kills itself to prevent the spread of cancer. The action of p53 is kept in check in healthy cells by its 
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antagonist, Mdm-2, an E3 ubiquitin ligase that specifically tags p53 for proteolytic destruction ( 17) 
(Figure 3). Pathways converging on the p53/Mdm-2 system can induce cell arrest or apoptosis either by 
inhibiting Mdm-2 or activating p53. The Ras pathway responds to growth signals and can become 
hyperactive from mutations in receptor tyrosine kinases (RTK), like epidermal growth factor receptor 
(EGFR). When overactive, the RAS pathway inhibits Mdm-2, the result being an accumulation of p53 
which induces expression of CKI leading to cell cycle arrest and apoptosis ( 17). This p53 check is 
important since roughly 30% of cancers have a hyperactive Ras pathway ( 18). Conversely, certain 
kinases (ATM and Chk2) directly phosphorylate p53, making it immune to Mdm-2 ubiquitylation. As 
before, p53 activates expression of CKI, causing cell cycle arrest and apoptosis. 
The Anaphase Promoting Complex/Cyclosome 
The anaphase promoting complex (APC) is a master regulator of several key checkpoints during 
mitosis and is being explored for its regulatory activity in other aspects of the cell cycle. Here, the focus 
will be on the APC’s role in regulating mitosis. The APC is a large, 13 subunit E3 ubiquitin ligase. It can be 
found in two different forms, depending on the timing in mitosis. Early in mitosis, the APCCdc20 form (the 
APC core bound to the protein CDC20) dominates. Later in mitosis, the APCCdh1 form dominates. Each 
still has E3 ubiquitin ligase activity, differing only in their substrate specificity. The APCCdh1 form prefers 
substrates with D-boxes and KEN boxes. The consensus sequences for these domains are R-X-X-X-L-X-X-
X-X-N and K-E-N-X-X-X-E/D/N respectively ( 19). 
 Cyroelectron microscopy and immuno-locating experiments have begun to shed some light on 
the structure and organization of the APC, in both of its forms (Figure 4). The APC is formed around the 
central protein Apc1. On one side of Apc1 extends the “TRP arm,” composed of subunits Cdc23, Cdc16, 
Cdc26, Apc9 and Cdc27. The TRP arm associates with the variable Cdh1 or Cdc20 subunits, linking it to 
the main body of the APC. The exact stoichiometry of the arm in relation to the rest of the APC is 
unknown. It is possible that the number of TRP arms is variable. Current estimates range from one to 
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three arms. In principle, each one could be capable of associating with Cdh1 or Cdc20. The variable 
subunits Cdh1 and Cdc20 are thought to be the subunits that interact with and recruit the substrate, 
thereby giving the APC is different substrate preferences. It is still open to investigation weather Cdh1 
and Cdc20 first capture the substrate and then recruit it to the APC, or if the APC core proteins first 
capture Cdh1 or Cdc and then recruit the substrates. An attractive explanation as to why Cdh1 and Cdc 
are at the end of a long arm is so that the APC can accommodate an array of difference substrates sizes ( 
20). 
 Opposite the Cdh1 and Cdc20 subunits lies the E3 ubiquitination domain of the APC, specifically 
the subunit Apc11. This subunit is responsible for taking an activated ubiquitin molecule from UBC (an 
E2 protein) and transferring it to whatever substrate happens to be bound. Apc11 has a zinc RING finger 
motif which it used to transfer ubiquitin to its substrate without itself ever forming a covalent bond to 
the ubiquitin. RING finger motifs are seen in other E3 ubiquitin ligases, such as SCF (Skp/Cullin/F-box) ( 
20). 
 One of the most well known activities of the APC is promoting the transition from metaphase to 
anaphase by promoting the separation of sister chromatids. Once all of the mitotic spindles have 
attached to the kinetochores, APCCdc20 ubquitinates securin, which normally inhibits the protease 
separase. Sepase then degrades the cohesin protein bridge linking sister chromatids, allowing them to 
separate and anaphase to progress. The system is so sensitive that one unattached mitotic spindle is 
enough to shut down the pathway, ensuring that each daughter cell will receive one copy of each 
chromosome ( 19,20). 
 It is easy to see how disruption of this master cell cycle regulator could cause significant damage 
to the cell, ultimately leading to cell cycle arrest and apoptosis. However, not all cell deaths are equal. 
Apoptosis refers to a very specific and regulated form of cell suicide and differs significantly from 
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necrosis, in which a cell explodes in an uncontrolled manner. These differences are important when 
discussing both cancer and viral infections. 
 
Necrosis Versus Apoptosis 
 Necrosis and apoptosis are two general ways in which eukaryotic cells are killed. Necrosis 
typically takes place under toxic conditions, such as during a pathological reaction, and is considered to 
be a passive degeneration of cells. This type of cell death is characterized by loss of integrity of the cell 
membrane and the loss of control of cellular functions of internal cellular organelles. By contrast, 
apoptosis can be induced either by the cells themselves (intrinsic) or by cell of the immune system 
(extrinsic), as a type of “cell suicide.” Apoptosis is characterized by cell shrinkage, perinuclear 
condensation of chromatin, fragmentation of nuclei, and fragmentation of chromosomal DNA ( 21). 
After these events take place, the cell fragments form into membrane-enclosed bodies and are 
phagocytosed by neighboring cells ( 1). The ability of neighboring cells to phagosize the apoptotic cells 
allows apoptosis to be more efficient and less detrimental to cell tissue than necrosis ( 7). 
 two routes through which apoptosis can occur, via the extrinsic or intrinsic pathway (Figure 5). In the 
extrinsic pathway, an outside cell directs the target cell to commit to apoptosis through the interaction 
of membrane proteins. The inducing cell presents the membrane protein FasL (Fas Ligand), which docks 
with the target cell’s Fas transmembrane proteins, which forms a trimer. The cytoplasmic protein FADD 
(Fas Associating Death Doman) binds to the cytoplasmic side of the Fas transmembrane proteins, and 
serves as an adapter protein for recruiting procaspase-8 and procaspase-10. These inactive initiator 
caspases require protolytic processing before they themselves become active proteases. Due to their 
physical proximity, procaspase-8 and procaspase-10 are able to cleave and activate each other, 
producing Caspase-8 and Caspase-10. Caspase-8 and Caspase-10 then proteolytically convert 
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procaspase-3 to caspase-3, the so called executioner caspase because it degrades many of the cellular 
targets of apoptosis ( 22). 
 The route of intrinsic apoptosis is less well known. What is certain is that it is triggered by the 
release of cytochromeC from the mitochondrial intermembrane space. Together, cytochromeC and 
Apaf-1 (Apoptin protease activating factor) form the apoptosome, which cryoelectron microscopy has 
shown to resemble a wheel with six bent spokes. The apoptosome activates procaspase-9, which in turn 
activates procaspase-3 using similar proteolytic processing strategies as for the extrinsic pathway. 
Caspase-3 then degrades it cellular targets. The events that link apoptotic stimuli, such as DNA damage, 
to the downstream events of the intrinsic pathways are not yet established ( 22). Thus the molecular 
events linking CKI expression by p53 and cell cycle arrest to apoptosis are not well understood. 
Virus-induced Apoptosis 
 Cell use apoptosis as a means of limiting viral egress. Results from a study done with mutant 
insect viruses ( 21) show that virus-induced apoptosis can be a host defense mechanism as a result of 
premature lysis of infected cells that have not finished replicating their genome. This leads to a loss or 
suppression of virus multiplication in the host organism ( 21). This hypothesis, however, seems to be 
increasingly challanged by the fact that animal viruses have developed two strategies for overcoming 
premature apoptosis or apoptosis itself: rapid multiplication and an antiapoptosis gene. Through rapid 
multiplication, viruses are able to completely replicate their genome before apoptosis takes place ( 21). 
RNA viruses are particularly good at rapid multiplication, completing their life cycle before apoptosis-
mediated suppression is effective. From an evolutionary standpoint, it makes sense that RNA viruses 
have developed the means for rapid multiplication before apoptosis because they have a relatively small 
number of genes compared to DNA viruses so it would be more difficult to acquire another gene ( 21). 
DNA viruses on the other hand, have an antiapoptosis gene that prevents apoptosis in infected cells. 
Examples of such DNA viruses with an antiapoptosis gene would be poxviruses, herpesviruses and 
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adenoviruses. HIV has an antiapoptosis gene even though it is an RNA virus. HIV is a retrovirus that has a 
“long incubation period (for reverse transcription, integration into host chromosome and expression of 
virus genome with fine regulations), [so] it seems easy and reasonable to have an antiapoptosis gene 
instead of rapid multiplication of virus” ( 21). 
However, apoptosis is not always used a defense mechanism of the cell. Viruses have the ability 
directly induce apoptosis for their advantage. The first virus found to induce apoptosis directly was an 
adenovirus mutant (E1B-19K). It was found that the adenovirus mutant induces extensive apoptosis in 
infected cells and that the adenovirus contains an antiapoptosis gene. Over the years, many RNA and 
DNA viruses have been discovered to induce apoptosis in eukaryotic cells ( 21). DNA viruses induce 
apoptosis differently than RNA viruses. Most large DNA viruses only induce apoptosis when their 
genome acquires a mutation and they lose a particular function of a gene while most RNA viruses induce 
apoptosis under conditions that allow sufficient virus multiplication ( 21).   
 There are viruses that are able to selectively induce apoptosis in cancer cells while leaving most 
normal cells untouched. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), or Apo 2 ligant 
(Apo2L), is able to do so through an extrinsic pathway (see Figure 5). It is a member of a tumor necrosis 
factor (TNF) family that is able to induce apoptosis through the binding of its ligand to a death receptor. 
It also induces apoptosis independently of the p53 tumor-suppressor gene, which is important since this 
pathway is mutated in approximately half of all cancer ( 23). Thus transformed cell can be told to “shut 
down” even if they can no longer regulate the cell cycle. The chicken anemia virus (CAV) is different in 
that it does itself infect cancer cells. However, intriguing evidence has shown that its Apoptin protein is 
able to selectively kill cancer cells via an intrinsic pathway independent of the p53 tumor-tumor 
suppressor gene and cannot be blocked by Bcl-2 ( 1,24). 
In order to determine how exactly Apoptin induces apoptosis of transformed cells, further study 
needs to be done on the roles of the rate of cell division, shuttling, and multimerization. It has been 
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shown that nuclear localization in tumor cells is required for apoptosis. It has also been shown that in 
order for apoptosis to take place, Apoptin needs to interact with the APC1 and does so most efficiently 
when multimerized ( 2). The goal of this project was to discover how nucleocytoplasmic shuttling and 
multimerization are related, and what roles they play in selectively inducing apoptosis in cancer cells. 
This was done through a more expansive probing of the NES with point mutations (I40A, T43A, L44A, 
L46A) to try to uncouple nuclear export and multimerization. A senior thesis project done by DeConti 
and Medeiros (2005) illustrated that they had retained multimerization by inducing a point mutation in 
the NES (I37A) ( 25). This project also conducted additional testing on ApI37A to discover if nuclear 
export was retained or lost. 
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Materials and Methods 
Site Directed Mutagenesis 
Site directed mutagenesis was accomplished using the “megaprimer” approach. Forward (F) and reverse 
(R) primers of ~40nt in length were designed to be complementary to Apoptin, except for the desired 
base changes, which were located in the center of the primer. N and C terminal fragments of Apoptin 
were generated by PCR using forward and reverse primers for Apoptin.  Primers ApF and SDMR 
generated the N-terminal fragment, while ApR and SDMF generated the C-terminal fragment. N and C-
terminal fragments (the “megaprimers”) were gel extracted and combined in an approximate 
stoichiometric ratio of 1:1. A second PCR was done with ApF and ApR primers, and 1:10 serial dilutions 
of the megaprimers. The resulting mutated full length Apoptin from the PCR with the most dilute 
megaprimers was used in subsequent cloning. All other cloning was accomplished with standard 
techniques. 
 
SDM Primers: 
Ap F 
 
5’ atgaacgctctccaagaagatactccaccc 3’ 
Ap R 
 
5’ ttacagtcttatacgcctttttgcggttcggg 3’ 
I37A F 
 
5' cagagagatccggattggtgccgctggaattacaatcactc 3' 
I37A R 
 
5' gagtgattgtaattccagcggcaccaatccggatctctctg 3' 
I40A F 
 
5' gatccggattggtatcgctggagccacaatcactctatcgctgtg 3' 
I40A R 
 
5' cacagcgatagagtgattgtggctccagcgataccaatccggatc 3' 
T43A F 
 
5' gtatcgctggaattacaatcgccctatcgctgtgtggctg 3' 
T43A R 
 
5' cagccacacagcgatagggcgattgtaattccagcgatac 3' 
L44A F 
 
5’ gctggaattacaatcactgcctcgctgtgtggctgcgcgaatgc 3’ 
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L44A R 
 
5’  gcattcgcgcagccacacagcgaggcagtgattgtaattccagc 3’ 
L46A F 
 
5’ ggaattacaatcactctatcggcctgtggctgcgcgaatgctcg 3’ 
L46A R 
 
5’ cgagcattcgcgcagccacaggccgatagagtgattgtaattcc 3’ 
 
Yeast 2-Hybrid Assay 
The yeast 2-hybrid assay was carried out in Y190 yeast cotransformed with the appropriate pACT2 and 
pGBK plasmids and selected for on SD –tryptophan –leucine plates, as described elsewhere ( 26). 
Colonies were lifted on VWR Blotting paper 703, freeze fractured in liquid nitrogen and β-gal was 
detected using X-gal in Z-buffer as described elsewhere ( 26). The assay was incubated overnight at 30C 
before imaging. 
 
Fluorescence Microscopy 
H1299 cells were grown on cover slips for 24 hrs and transfected using Effectene from Qiagen per 
manufacturer’s instructions. The plasmid pEGFP-C1 contained truncations of the Apoptin mutants so as 
to lack the NLS. (Truncation primer: Ap244R) 24 hrs later, cells were washed with PBS and fixed with 2% 
paraformaldehyde in PBS on an orbital shaker for 15 minutes. The cells were again washed with PBS and 
mounted onto slides with a drop of mounting media (50% glycerol, 100 mM Tris pH 7.5, 2% DABCO and 
DAPI). Cells were imaged by fluorescence microscopy. 
  
22 
 
Results 
Site-Directed Mutagenesis of Apoptin NES  
In order to uncouple multimerization from nuclear export, point mutations were induced at the 
most conserved residues of the canonical NES of Apoptin. Inducing mutations of a canonical 
multimerization sequence was not possible because there is no known canonical multimerization 
sequence.  Sequence alignments of other various canonical viral and mammalian NESs with Apoptin NES 
were done to illustrate the most conserved residues that likely play a key role in nuclear export (Figure 
6, section (A)). ApL44 and ApL46 are the most conserved residues among all of the selected NESs of 
comparison. ApT43 of is also conserved among HTLV-1 Rex NES, MDM2 NES, p63 NES, and p73 NES 
except that their residues are all serine. Since threonine and serine are both very similar amino acids in 
that their side chains are uncharged and polar they are essentially interchangeable amino acids.  ApI40 
is also highly conserved among all of the NESs. As is the case with ApT43, ApI40 is interchangeable with 
the leucine in the same position of all the selected NESs (except for MDM2 NES) because both amino 
acids have large non-polar side chains and behave similarily. ApI37 appears to be less conserved when 
compared to the conservation of the other canonical amino acids; however, there is still conservation 
between ApI37and HIV-1 Rev NES, p63 NES, p73 NES and p53 NES.  
In this study four canonical residues of Apoptin’s NES, isoleucine 40, threonine 43, leucine 44 
and leucine 46, were all individually mutated to alanine through PCR site-directed mutagenesis. The NES 
of Apoptin has been shown to interact with the major exportin Crm1. Previous studies in which Crm1 
dependent canonical NES residues were mutated to alanine, a small neutral amino acid, and showed no 
interaction with Crm1 therefore alanine was the chosen amino acid to mutate the canonical residues to. 
Also, in addition to L44 and L46 being highly conserved residues of NESs, previous studies have shown 
that an Apoptin double mutant, ApL44A-ApL46A, results in the loss of nuclear export and 
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multimerization. This reveals that L44 and L46 are likely key players in Crm1 mediated nuclear export 
and multimerization. Isoleucine 37 was previously mutated to alanine and was additionally used in this 
study. I40, T43, L44 and L46, along with I37 were the five amino acid residues most conserved that 
would most likely have an effect on nuclear export and multimerization when mutations were induced 
at these residues (Figure 6, section (B)). Once ApI40A, ApT43A, ApL44A and ApL46A were created, DNA 
sequencing results verify successful point mutations and homology throughout the rest of the Apoptin 
gene for all four Apoptin mutants (Figure 6, section (C)).  
Secondary Structure Predictions 
As virtually no structural data is available for Apoptin, two secondary structure prediction 
programs (JPRED and SSPRO) were used to get a crude ideas of any secondary structures present in 
Apoptin. Both programs agreed that Apoptin is largely devoid of secondary structure, except for an 
extended peptide near the N-terminus and two α-helices at the C-terminus (Figure 7) . Perhaps the 
general lack of secondary structure could explain the difficult in crystallizing Apoptin, as well as the 
inconclusive results of the circular dichroism. Significantly, the extended peptide entirely covers the NES 
and extends several upstream residues. To check that the prediction programs could correctly 
determine the secondary structure of known NES, the programs were asked to predict the secondary 
structures of SNUPN and p53, both of which have crystal structures of their NES. Both programs 
correctly predicted the SNUPN and p53 NESs to be in an α-helix, in aggrement with the crystal structures 
(Figure 7). While these controls do not prove that JPRED and SSPRO are 100% accurate in their 
secondary structure predictions of an NES, it does significantly boost the confidence of their predictions.  
There is less correlation between secondary structure and the NLS.  Apoptin’s NLS is known to 
be bipartite, comprised of two sites of containing three adjacent basic residues. The most C-terminal 
basic site overlaps partially at the end of the most C-terminal predicted α-helix, while the other basic 
site and other predicted α-helix do no align at all (data not shown). While there is poor correlation 
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between Apoptin’s NLS and the predicted α-helices, it is significant the predicted extended peptide in a 
largly structureless protein correlates extremely well with Apoptin’s NES.  While these results are not 
experimental, it is tempting to speculate that there might be a reason why the extended peptide 
overlaps with the NES, which is also found in Apoptin’s multimerization domain. A more complete 
consideration of this point, and the relation between the NES and multimerization, can be found in the 
discussion section. 
Y190 Yeast 2-hybrid Assay  
The yeast 2-hybrid assay assessed the retention of multimerization through a double 
transformation of Y190 yeast with pGBKT7 and pACT2 plasmid vectors containing Apoptin and/or the 
Apoptin mutants. All five mutants, ApI37A, ApI40A, ApT43A, ApL44A, and ApL46A were ligated into 
pGBKT7, a plasmid vector that contains the TRP1 gene and a DNA binding domain (DBD), half of the 
necessary transcription factor to turn on the Gal4 promoter. ApWT was previously ligated into pACT2, 
the second plasmid vector used in the yeast 2-hybrid system. pACT2 contains the second half of the Gal4 
transcription factor, the transactivating domain (TAD) that binds to RNA polymerase II for transcription 
initiation,  and also the LEU2 gene. The Gal4 promoter is also under control of LacZ which when 
transcribed, produces β-galactosidase whose artificial substrate when cleaved yields galactose and 5-
bromo-4-chloro-3-hydroxyindole, a product that stains colonies blue. The DBD of the pGBKT7 vector and 
the TAD of the pACT2 vector when brought into close proximity to one another by a protein-protein 
interaction, will recruit RNAPII to the Gal4 promoter and transcribe the LacZ (Figure 8, section (B)). Y190 
yeast were transformed with both pGBKT7 and pACT2 vectors and plated onto SD –Leu/-Trp plates to 
confirm that the yeast indeed were transformed with both vectors. The transformed yeast that took up 
both vectors would express the LEU2 gene from the pACT2 vector and the TRP1 gene from pGBKT7 and 
be able to grow on the plates without leucine or tryptophan. Untransformed Y190 did not grow on the 
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SD–Leu/-Trp plates verifying that Y190 yeast require both plasmids to express leucine and 
tryptophan(Figure 8, section (A), panel 2B).  
For the second half of the yeast 2-hybrid assay, we lifted the colonies off each SD-Leu/-Trp plate 
with 3mm whatman paper, flash fractured them in liquid nitrogen, and soaked the fracture colonies in 
X-gal to induce Β-galactosidase activity if present. The positive control, pACT2-ApWT /pGBKT7-ApWT, 
showed β-galactosidase acitivy (Figure 8, section (A), panel 1A).  Wild-type Apoptin was used as the 
positive controls for this assay because it is well known that Apoptin extensively multimerizes with itself. 
The negative control –pACT2/-pGBKT7, showed no β-galactosidase activity (Figure 8, section (A), panel 
1B). This negative control illustrated no β-galactosidase activity due to the missing inserts in both of the 
vectors so the protein-protein interaction was unable to occur to allow the DBD and TAD to turn on the 
Gal4 promoter for transcription. All five of the mutants illustrate β-galactosidase activity and as a result 
they all have retained the ability to multimerize (Figure 8, section (A), panels 2A, 3A/B, and 4A/B) 
Subcellular Localization of Apoptin mutants. 
Fluorescence imaging of mutants Apoptins fused to GFP revealed that point mutation of 
conserved residues in the NES change subcellular localization. As compared to GFP alone, GFP-ApT43A, 
GFP-ApL44A and GFP-ApL46A showed a clear cytoplasmic localization consistent with a functioning NES 
(Figure 9). The cytoplasmic localization is consistent with the localization of GFP-Apwt as reported 
previously ( 2). This data indicates that T43, L44 and L46 alone are not essential for nuclear export. It is 
interesting to note, however, that the double mutant L44AL46A has been shown to abrogate nuclear 
export. Either L44 alone or L46 alone is required for nuclear export, but the presence of both is not 
required.  
Mutant ApI37A showed a strong reduction of nuclear export, adopting a diffuse localization 
(Figure 9). The partitioning between the nucleus and the cytoplasm was more equal than even the GFP 
control. The GFP control shows a slight bias towards a nuclear localization. This difference could indicate 
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very weak NES in the I37A mutant. However, the significant result is that mutation of a single conserved 
hydrophobic residue in the NES can almost completely knock out nuclear export of Apoptin. Because Ap-
I37A was shown to still multimerize in the yeast 2-hybrid assay, these results show that it is possible to 
uncouple nuclear export from multimerization in Apoptin despite the fact that they have overlapping 
dowmains.  
Mutant ApI40A shows partial loss of nuclear export. In some cells, GFP-ApI40A adopted a diffuse 
localization, identical to the localization of GFP-ApI37A. In other cells, nuclear export was only partially 
disrupted, with significant amounts of GFP-ApI40A observed in the nucleus (Figure 9). The levels of GFP-
ApI40A in the nucleus were noticeably higher than for mutants GFP-ApT43A, GFP-ApL44A or GFP-
ApL46A (Figure 9). It is possible that the observed reduction in NES activity and the cell to cell variability 
in localization are controlled by two different mechanisms. That is, one mechanism controls if GFP-
ApI40A is excluded from the nucleus and another mechanism controls how much is excluded from the 
nucleus. However, it is more tempting to speculate that these two observations may be functionally 
related, with the activity of nuclear export existing along a continuous spectrum. However, the trivial 
explanation that CRM1 is differentially expressed at different stages of the cell cycle is unlikely, as it has 
been shown that CRM1 protein levels are constant throughout the cell cycle, although CRM1 mRNA 
levels do rise and fall with the cell cycle ( 27). Perhaps an extra cellular factor modifies Apoptin to 
regulate its export in a cell-cycle dependent manner. This would be in line with the majority of CRM1 
substrates, which are differentially exported because of their role in cell cycle control ( 27). 
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Discussion 
 Apoptin is a protein from the Chicken Anemia Virus that has the unique ability to induce 
apoptosis in transformed and cancerous cells, but not primary cells. Apoptin triggers apoptosis through 
a p53-independent pathway, which is significant since roughly half of all cancers are insensitive to p53-
mediated apoptosis, owing to a mutated pathway. A dazzling array of mutations in any one of a sea of 
regulatory proteins can cause cancer. The study of Apoptin is important because the protein is somehow 
able to distinguish between a wide variety of transformed and primary cells, recognizing some common 
biochemical difference. Not only can it specifically recognize cancerous cells, but it can kill them in a 
manner that it not dependent on the specific mutation that caused the cancer. Thus Apoptin’s killing 
abilities are specific enough to leave primary cells unharmed, but broad enough to recognize cancers 
caused by different genetic mutations. 
 Two significant characteristics of Apoptin have provided clues as to Apoptin’s selection 
mechanism. First, Apoptin shuttles between the nucleus and cytoplasm in both primary and 
transformed cells using an N-terminal NES and C-terminal NLS. However, in primary cells, Apoptin 
partitions into the nucleus and in transformed and cancerous cells, Apoptin partitions into the nucleus. 
Previous studies suggest differential activity of the NES is responsible for the characteristic partitioning ( 
2). Second, Apoptin forms large multimers in vivo and is able to shuttle between the nucleus and 
cytoplasm at least as a dimer. Significantly, the multimerization domain overlaps with the NES, opening 
the possibility that multimerization and nuclear export are functionally related. In line with this idea, 
prior to this study all mutations that disrupted nuclear export also disrupted multimerization, suggesting 
nuclear export might depend on multimerization. However, this study mutated a greater number of 
conserved hydrophobic residues in the NES and found that two of the mutants, I37A and I40A, lost 
nuclear export while retaining multimerization.  
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Generating Mutants and Assessing Multimerization 
Apoptin contains a canonical NES that overlaps with the domain for multimerization and this 
study illustrates that these activities can definitively be uncoupled. Through sequence alignments of viral 
and mammalian NESs with the NES of Apoptin, we were able to identify the most conserved residues 
that were likely to affect recognition by Crm1 in an effort to uncouple nuclear export from 
multimerization. The most conserved residues, mostly hydrophobic, were I37, I40, T43, L44, and L46.  It 
was hypothesized that a mutation of one these key residues would lead to the loss of nuclear export 
and/or multimerization. A previous study showed that the replacement of the NES of Apoptin with 
another NES lead to the loss of multimerization. The same study also illustrated that a double mutation 
of L44 and L46 to alanines lead to the loss of both nuclear export and multimerization. This result left 
the interesting question of if single mutations at L44 and L46 could lead to the retention or loss of 
nuclear export and/or multimerization.  
A yeast 2-hybrid assay was first done in this study to assess the protein-protein interaction of 
the five Apoptin mutant NESs with ApWT. Each mutant was fused to the DNA biding domain (DBD) of 
GAL4 and ApWT was fused to the trans-activiating domain (TAD) of GAL4; when the DBD and TAD are 
brought into close proximity through protein-protein interactions, the Gal4 promoter is turned on, 
expressing the reporter protein β-galactosidase. After freeze fracturing the yeast in liquid nitrogen, the 
β-galactosidase can be easily detected, as it the breakdown of X-gal into galactose and the blue dye 5-
bromo-4-chloro-3-hydroxyindole. Results of this assay showed that all five mutants had β-galactosidase 
activity, indicating the mutant Apoptins retained multimerization. This indicates that single point 
mutations at these key hydrophobic residues does not disrupt the domain for multimerization. This 
could be because either A) point mutations do not disrupt the secondary structure of the domain for 
multimerization so the interaction surface between Apoptin molecules is still intact or B) the mutated 
residues do not participate directly in the Apoptin-Apoptin interactions. 
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Subcellular Localization of Apoptin Mutants. 
Next we assessed the effect each mutation had on nuclear export H1299 cells, a non-small-cell-
lung-carcinoma line . We truncated Apoptin to remove the NLS, fused it to the C-terminus of GFP and 
transformed each of the tagged truncation mutants into H1299 cells. Fluorescence imaging of each 
mutant Apoptin fused to GFP revealed that point mutations of conserved residues in the NES change 
subcellular localization. As compared to GFP alone, GFP-ApT43A, GFP-ApL44A and GFP-ApL46A showed 
a clear cytoplasmic localization consistent with a functioning NES. The cytoplasmic localization is 
consistent with the localization of GFP-Apwt as reported previously ( 2). This data indicates that T43, L44 
and L46 alone are not essential for nuclear export. It is interesting to note, however, that the double 
mutant L44AL46A has been shown to abrogate nuclear export. Either L44 alone or L46 alone is required 
for nuclear export, but the presence of both is not required.  
Mutant ApI37A showed a strong reduction of nuclear export, adopting a diffuse localization. 
This significant result shows that mutation of a single conserved hydrophobic residue in the NES can 
completely knock out nuclear export of Apoptin. Because Ap-I37A was shown to still multimerize in the 
yeast 2-hybrid assay, these results show that it is possible to uncouple nuclear export from 
multimerization in Apoptin, despite the fact that they have overlapping domains.  
Mutant ApI40A shows partial loss of nuclear export. In some cells, GFP-ApI40A adopted a diffuse 
localization, identical to the localization of GFP-ApI37A. In other cells, nuclear export was only partially 
disrupted, with significant amounts of GFP-ApI40A observed in the nucleus. Significantly, the levels of 
GFP-ApI40A in the nucleus were noticeably higher than for mutants GFP-ApT43A, GFP-ApL44A or GFP-
ApL46A. One possibility is that Ap-I40A partitions differently depending on the stage in the cell cycle. 
This would be in line with the majority of CRM1 substrates, which are differentially exported because of 
their role in cell cycle control ( 27). If this is true, the trivial explanation that CRM1 is differentially 
expressed at different stages of the cell cycle is unlikely, as it has been shown that CRM1 protein levels 
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are constant throughout the cell cycle, although CRM1 mRNA levels do rise and fall with the cell cycle ( 
27). Perhaps an extra cellular factor modifies/interacts with Apoptin to regulate its export in a cell-cycle 
dependent manner. However, post translation modifications (PTM) seem difficult to rationalize, given 
that no PTM targets isoleucine and that no other mutants show variable subcellular partitioning. 
 
Apoptin’s NES: N-terminus versus C-terminus 
The consensus sequence for NESs has been proposed by numerous sources to be Φ(X)2-3Φ(X)2-
3ΦXΦ, where Φ represents hydrophobic amino acids (Lys, Val, Ile, Phe, or Met) and X is any amino acid ( 
12,13).  Apoptin’s NES is IRIGIAGITITLSL and residues I37 through L46 (IAGITITLSL) fit the canonical 
sequence, while N-terminal residues I33 through G36 (IRIG) do not fit the canonical sequence, even 
though those residues have been experimentally validated as part of the NES. Sequence alignments of 
various known NESs with Apoptin’s NES illustrates that the most conserved residues are the C-terminal 
hydrophobic residues L44 and L46 of Apoptin (ΦXΦ with respect to the canonical NES) (Figure 6, section 
(A)). One would expect that these C-terminal residues, L44 and L46, are the most important residues of 
NESs since they are most conserved and when double mutants are produced at these residues, nuclear 
export is lost.  That would make the C-terminal end of NESs more important for NES recognition by 
CRM1.  Contrary to this analysis, our data suggests that the less conserved N-terminus of Apoptin’s NES 
(ApI37A and ApI40A) is more important for CRM1 binding, while the more conserved C-terminus 
(ApL44A and ApL46A) is less important for CRM1 binding. Since it took a double mutant to knock out 
nuclear export at the C-terminus (ApL44A-L46A) and single mutants more towards the N-terminus (I37A 
and I40A), it appears that the C-terminus is more tolerant to mutations while the N-terminus is more 
sensitive to mutations. Nonetheless, our data shows the degree of conservation of a residue between 
Apoptin’s NES and the canonical NES does not correlate well a residue’s importance in nuclear export. 
This results could hint at the possibility that Apoptin’s NES binds CRM1 in a manner different than the 
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canonical leucine rich NES (LR-NES). In line with this idea are the results of secondary structure predition 
programs, which predict an α-helix in the canonical SNUPN NES, but predict an exended peptide in 
Apoptin’s NES. 
Single mutations at residues ApL44 and ApL46 each showed the retention of export, illustrating 
that CRM1 still has the ability to recognize Apoptin’s NES. As previously stated, double mutants at these 
residues completely abolishes nuclear export. One explanation for the difference in this data between 
the double and single mutants is that perhaps CRM1 recognition of an NES requires a general 
hydrophobic residue in the area of extreme C-terminal end of an NES. By having either ApL44 or ApL46 
present CRM1 is still able to make contact with one of the hydrophobic residues at the C-terminus of 
Apoptin and recognize it as an NES. Another explanation for the difference in nuclear export between 
the double mutants of ApL44A-ApL46A and single mutants of the same residues is that perhaps 
knocking out both residues in a double mutant changes the way the NES folds and therefore inhibits the 
interaction between CRM1 and Apoptin’s NES. The double mutant NES could fold in such a manner as to 
completely abolish any interaction with CRM1 at the C-terminal end. Such a change in secondary 
structure might also be responsible for ablating multimerization in L44AL46A double mutant. On the 
other hand, the single mutants ApL44 and ApL46A retained nuclear export, which could be because the 
single mutants may not have an effect on the secondary structure of the NES; the secondary structure 
could still be in its normal form in which CRM1 most efficiently binds the NES. It is frustrating to leave 
this at speculation, but all previous attempts to determine Apoptin’s crystal structure have failed and 
circular dichroism revealed no secondary structure. 
Apoptin’s canonical NES and CRM1: Sequence and Structure 
Using the nuclear export data obtained in this study, the canonical NES of Apoptin, and 
information about the canonical NES of SNUPN (who’s NES is also recognized by CRM1) we have 
deduced the key residues in Apoptin’s NES needed for CRM1 mediated nuclear export. We also 
32 
 
postulate a possible secondary structure for Apoptin’s NES that could explain Apoptin’s ability to shuttle 
as a dimer. 
The exportin CRM1 binds LR-NES. The following summary of CRM1 binding is based on the 
recent cocrystalization of CRM1 with SNUPN (a canonical LR-NES containing protein)( 12). It is the only 
cocrystalization of CRM1 with an NES to be produced thus far. The interaction surface of CRM1 that 
binds to the NES is a hydrophobic groove formed by 3 helices. The hydrophobic groove starts out wide 
and then gets progressively narrower until it is just a narrow channel. The widest part of the 
hydrophobic groove binds the N-terminal region of the NES which is in an α-helix, while the narrowest 
part of the hydrophobic channel binds the C-termial region of the NES, which has been squeezed into an 
extended peptide conformation. Analysis of crystallographic structures LR-NESs show that LR-NESs 
typically contain hydrophobic residues spaced 2-3 amino acids apart that fit the canonical NES, are rich 
in acidic amino acids which make contact with flanking basic residues on CRM1, and are very flexible 
themselves or are near very flexible regions of the protein. A large percentage of NESs tend to be in an 
α- helix conformation, although there are a small percentage of NESs in an extended peptide 
conformation such as a B-sheet or coil. The hydrophobic amino acids align all on the same side of the 
helix that contacts CRM1. LR-NES are also enriched so serines, which could help solvate the back of the 
NES. 
Snurportin 1 (SNUPN) is a protein who’s LR NES is also recognized by Crm1. SNUPNs NES is 
located at the extreme N-terminus of the protein and consists of residues 1-16 (MEELSQALASSFSVSQ). 
The N-terminal region of the NES is in an α- helix conformation (MEELSQALASS) while the extreme C-
terminal end (FSVSQ) is part of a very long extended peptide/loop structure. The loop structure at the C-
terminus of the NES makes the NES itself a very flexible structure.  Like Apoptin’s NES, only a portion of 
the NES fits the canonical NES. Residues LSQALASSFSV are part of the canonical NES, while the extreme 
N-terminal NES residues, MEE, and extreme C-terminal residues, SQ, are not part of the canonical NES, 
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but are still part of the entire NES. Residues M1, L4, L8, F14 and V16 of SNUPN’s NES interact directly 
with a hydrophobic groove of CRM1. Acidic side chains (E2 and E3) of SNUPN’s NES help to interact with 
basic residues (L560 and L522) that flank the hydrophobic groove of CRM1. SNUPN additionally contains 
a second NES epitope consisting of mainly basic residues that help to stabilize the main NES with an 
acidic patch on CRM1.  The N-terminal α- helix of SNUPN’s NES binds to the wider area of CRM1’s 
hydrophobic pocket and the extended loop of the C-terminal end of SNUPN’s NES fits in the narrow 
channel after the bottleneck of CRM1s NES binding pocket.  
As illustrated by mutants ApI37A and ApI40A who both lost nuclear export, both hydrophobic 
residues ApI37 and ApI40 play a role in CRM1 recognition of Apoptin’s NES. Double mutant ApL44A-
ApL46A lost nuclear export in another study ( 2), while in this study single mutants of L44 and L46 
retained nuclear export, which indicates that the C-terminal end of Apoptin’s NES does play a role in 
CRM1 recognition of Apoptin’s NES.  Apoptin’s canonical NES is IAGITITLSL, and corresponds to residues 
37 through 46. However there are more NES residues at the extreme N-terminal end of the entire NES 
and within that region, there are 2 hydrophobic residues, I33 and I35 that could potentially interact with 
CRM1. SNUPN’s residues M1, L4, L8, F14, and V16 interact directly with CRM1; from our experimental 
data and from data previously done in another study, one could deduce that Apoptin’s residues I37, I40, 
L44 and/or L46 directly interact with CRM1. One could also speculate that either I33 or I35, residues of 
the N-terminus of Apoptin’s NES that do not match the canonical NES, could interact with CRM1 since 
SNUPN’s M1, which is not a part of the canonical NES, also interacts with CRM1 (Figure 10).  
 Apoptin’s amino acid sequence was run through a secondary structure prediction program and 
was predicted to have an extended peptide conformation in the NES (CITE). As secondary structure 
prediction programs are not near 100% accurate, we put SNUPN and p53 through the same prediction 
program as a control. SNUPN was predicted to have an α-helix at the N-terminal, but not C-terminal end 
of its NES, which matches with the crystal structure. Also p53 was correctly predicted to have an α-helix 
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throughout its NES, which also matches solved crystal structures ( 28) (Figure 7). As found by Leliveld et 
al. (2003) through circular dichroism, Apoptin is largely devoid of helical structures ( 8), so it is possible 
that Apoptin’s NES is in a different conformation than most of its LR-NES counterparters that are in an α- 
helix conformation. Although the NESs of SNUPN and Apoptin may have different secondary structures, 
it seems safe to assume that all proteins that are exported by CRM1 must interact with CRM1 in a very 
similar manner. Key hydrophobic residues in the NES need to interact with CRM1’s hydrophobic residues 
for export. As of now, there is no reason to believe that the correct positioning of NES hydrophobic 
residues could only be accomplished by an α-helix. It’s possible that Apoptin does adopt an extended 
peptide conformation since it is believed that NESs in a non α-helix conformation could still be 
recognized by CRM1 due to the wideness of CRM1’s N-terminal NES interaction surface. Apoptin could 
adopt an extended peptide conformation such as a B-sheet for the N-terminal region of the NES 
(residues I33 through T43), and an extended peptide (either in a coil or a B-sheet conformation) at the 
extreme C-terminus of the NES (L44 through L46) to fit within CRM1’s narrow hydrophobic channel that 
binds the C-terminal ends of NESs. In addition, it seems almost mandatory that the hydrophobic 
residues of an NES that interact with CRM1 be on one side of its secondary structure in order to interact 
with CRM1’s hydrophobic interface. Indeed, the key hydrophobic residues of SNUPN and p53’s NES are 
on one side of the α-helix and are then buried within CRM1’s hydrophobic groove at the CRM1-SNUPN 
interface. In sum, although the secondary structure was predicted to be different than SNUPN, it is 
speculated that Apoptin could potentially adopt an extended peptide conformation with key 
hydrophobic residues on one side of the extended peptide available for interaction with CRM1. 
Noncanonical Aspects of Apoptin’s NES 
Apoptin’s NES also differs from the canonical NES with regards to its non-hydrophobic residues. 
Alignments of experimentally validated NESs have revealed an enrichment of aspartic acid, glutamic 
acids and serine residues in the NES. Dong et al. (2009) have speculated that the acidic residues enhance 
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NES binding by being complementary to basic residues flanking CRM1’s NES binding site. The serine 
residues, they speculated, would cover the back of the NES α-helix to help solvate it. Analysis of 
Apoptin’s NES shows no aspartic or glutamic acid residues, either directly in the sequence or in the 
surrounding amino acids, suggesting that it does not use CRM1’s basic residues to aid its binding. This 
would make sense if Apoptin’s NES adapted an extended peptide conformation, as predicted by 
different secondary structure prediction programs. Assuming that the hydrophobic residues are all 
facing downward to contact the CRM1 NES binding site, an extended peptide conformation would orient 
the intervening residues facing up. Being more exposed to solvent than to the flanking side chains of 
CRM1, the orientation would prohibit the interaction of any acidic residues with the flanking basic 
residues. Conversely, when an NES adopts the more usual α-helix conformation, residues can be 
positioned such that they jut out to the side and make easier contact with nearby CRM1 residues. Thus 
the lack of aspartic acid and glutamic acid residues could be explained by the predicted extended 
peptide conformation being unable to position the acid residues to productively contact CRM1’s basic 
residues. 
Another amino acid that is enriched in NES’s is serine. Based on the crystal structure of SNUPN 
binding to CRM1, Dong et al. (2009) suggested that polar residues along the solvent exposed side of the 
NES α-helix would help to solvate it ( 12). In agreement with this idea, an enrichment in serine residues 
has been identified at positions within NESs ( 13). Taken together, these observations suggest that at 
least some NESs function as a flexible, independent tag that is not significantly bound up in the tertiary 
structure of the protein. If the α-helix of the NESs were a face of a globular protein, there would be no 
need to coat the back side with hydrophilic residues. While Apoptin’s NES has only one serine residue, it 
does have two nearby threonine residues. Again assuming Apoptin’s NES adopts the predicted extended 
peptide conformation, the three polar residues would be aligned to the same side, helping to solvate 
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the NES. The presence of the polar residues could be an indication that Apoptin’s NES functions as in 
independent motif, spatially separated from the main Apoptin fold.  
Thus, while Apoptin’s NES likely does not have an α-helix, a putative extended peptide 
conformation could allow for similar residue-positioning strategies. It would allow the hydrophobic 
residues to align downward, fitting into the hydrophobic pockets of CRM1, while allowing the 
hydrophilic residues to align upward, solvating the back of the NES. A limitation of the extended peptide 
conformation as compared to an α-helix conformation is that it would not allow for acidic residues to be 
positioned sideways to interact with CRM1 basic residues. Consistent with this idea, no acidic residues 
are found in or near Apoptin’s NES.  
 In addition to the LR NES of SNUPN there is also an NES region rich in basic residues in SNUPN 
that binds with an acidic patch on CRM1 near the hydrophobic NES binding site and is used to help 
stabilize and strengthen the weak SNUPN-CRM1 interface. Interestingly, there are an abundance of basic 
residues which make up the bipartile NLS of Apoptin that is located near the extreme C-terminus of the 
protein. Dong et al. (2009) speculate that since the proximity of the LR NES binding site and the acidic 
patch are so close on CRM1, that many CRM1 substrates may contain, in addition to their LR-NES, basic 
NES regions ( 12). It is complete speculation, but perhaps when CRM1 binds the NES of Apoptin, it 
induces a conformational change in Apoptin to essentially swing over the NLS to bind with the acidic 
patch on CRM1 to help stabilize the CRM1-ApNES interface.  This could help explain why Apoptin is 
believed to have little regular secondary structure since it has yet to be crystallized and circular 
dichroism has shown no secondary structure. NESs and NLSs are required to be flexible portions of 
proteins for easy access to exportins and importins. Since Apoptin is such a short protein (121 amino 
acids), and the NES is located at the N-terminal end and the NLS is located at the C-terminal end, it begs 
the question of how much regular structure can the protein have if the ends needs to be flexible and 
mobile.  
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Intermediary Export of I40A 
Site directed mutagenesis of Apoptin’s NES resulted in a spectrum of NES activity. Mutations 
ApT43A, ApL44A and ApL46A showed complete retention of export, while mutation ApI37A showed a 
complete loss of transport. Intermediary between these two extremes is mutation ApI40A, which in 
some H1299 cells shows complete loss of export, while in other H1299 cells, it shows varying amounts of 
nuclear export. These results show that nuclear export of Apoptin isn’t strictly on or off, and that in 
H1299 cells the same mutant can adopt different sub-cellular localizations. This observation may hint at 
more complex regulatory mechanism that mediate Apoptin export beyond simply binding to CRM1. 
Although more data is certainly needed to tease out the regulatory details, we will speculate on some 
possibilities here. 
One attractive possibility is that Apoptin’s export is somehow linked to the cell cycle. Cells in 
culture are at different stages in the cell cycle, and so could exhibit different Apoptin localization, if its 
export were coupled to the stage in the cell cycle. Indeed, a major class of proteins with NES are 
involved in cell cycle control. These proteins obviously need to be exported only at certain times in the 
cell cycle, and so it seems possible that Apoptin could be regulated by some of the same cell-cycle 
dependent mechanisms. But if the variability in localization of ApI40A is due to the stage of the cell 
cycle, why then is no variability observed in wild type Apoptin or any of the other mutants? This could 
be explained if a cell cycle dependent helper protein could assist Apoptin in binding to CRM1. The 
necessity of this helper protein would depend on the strength with which Apoptin’s NES binds to CRM1. 
In the wild type Apoptin or in mutations ApT43A, ApL44A or ApL46A, the NES binding to CRM1 would be 
strong, and would be stable regardless of the presence of a helper protein. Thus wild type, T43A, L44A 
and L46A Apoptin would always be exported. Conversely, the I37A mutation could be so destabilizing 
that it could not bind CRM1 even in the presence of the helper protein. In the case of I40A, the mutation 
could have an intermediary effect on CRM1 binding. The mutations could be disruptive enough such 
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that Apoptin doesn’t bind Apoptin on its own, but still has enough affinity for CRM1 that it can bind with 
the assistance of the helper protein. Thus Apoptin would only be exported at the stages in the cell cycle 
during which the helper protein is expressed. 
 Alternatively, the mutations in Apoptin affect how well it competes for CRM1 binding. Apoptin 
mutants T43A, L44A and L46A could have equal CRM1 affinity as does wild type Apoptin. These mutants 
would always strongly bind CRM1 and be exported. In contrast, ApI40A could have intermediary affinity 
for CRM1, and could be outcompeted for CRM1 binding by other cell-cycle dependent proteins. Thus a 
diffuse ApI40A could correlate to times of high CRM1 dependent export in which CRM1 is saturated and 
so preferentially exports strong binders. Similarly, nuclear exclusion of ApI40A could correlate to times 
of low nuclear export during which CRM1 can export low affinity binders. Clearly, further experiments 
are needed to provide data to distinguish among these possibilities. One particularly useful experiment 
would be to transfect a synchronous population of H1299. If ApI40A localization is still variable, then the 
difference could not be correlated to the stage of the cell cycle and is likely due to other cell to cell 
variablity. However if ApI40A localizes similarly in the synchronous cells, then it would point to a 
dependence on the stage of the cell cycle. It would be particularly convincing if the cells could be caught 
at the stage in the cell cycle where ApI40A is diffusely localized, since this is normally a relatively minor 
localization of ApI40A. 
Post Translational Modification of Apoptin’s NES 
It is unlikely that mutated residues that caused a change in Apoptin localization are the targets 
of differential post-translational modifications (PTM), which could influence localization. Both of the 
mutated residues that cause a change in nuclear export were isoleucines, which are not subject to post-
translational modification. It is possible that mutations I37A and I40A could distort the secondary 
structure, which could inhibit binding to the enzyme that adds the PTM. However, this is entirely 
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speculative and it is simpler to think that alteration in the secondary structure would directly inhibit 
CRM1 binding, rather than inhibiting binding of an enzyme that adds a PTM that prevents CRM1 binding. 
Relationship Between the NES and Multimerization 
The most significant result of this study is that multimerization and nuclear export of Apoptin 
are separable functions. Our findings are in contrast to previous studies in which all mutations that 
eliminated nuclear export also eliminated multimerization. Taken together, the data shows that nuclear 
export and multimerization are functionally related, and that only certain mutations are able to separate 
them. The simplest explanation for nuclear export and multimerization being related is that they both 
rely on the same amino acid residues to function. For example, the hydrophobic residues of p53’s NES 
align along one side of an α-helix and form a hydrophobic strip that participates in the tetramerization 
domain interactions. Thus mutating a conserved hydrophobic residue would not only prevent CRM1 
binding, but could also reduce or eliminate the affinities of the tetramerization domain. However, 
secondary structure prediction programs predict Apoptin’s NES to be in an extended peptide 
conformation, not an α-helix. Significantly, the extended peptide of the NES is the only secondary 
structure predicted in the multimerization domain. The lack of any predicted secondary structure 
elsewhere in the multimerization domain makes it even more tempting to speculate that the 
multimerization activity maps to the extended peptide of the NES, as it is difficult to see how a proteins 
could multimerize at an interface without a regular secondary structure.  
One speculative idea is that the extended peptide of the NES contributes to multimerization in a 
manner similar to amyloid plaque formation (Figure 11). Nelson et al. showed short extended peptides 
can stack in the standard Pauling-Corey parallel arrangement and form fibrils that show the essential 
features of amyloid plaques ( 29). The fibril is composed of two sheets that are held together by tightly 
interlocking amino acid residues, with each sheet being composed of a parallel stacking of extended 
peptides held together vertically by hydrogen bonding. The two sheets are arranged around a 21 screw 
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axis, so that they are rotated 180 degrees around the central axis, and staggered one half the length of 
the vertical repeating unit. A similar quaternary structure could be formed by the extended peptide of 
the NES. Most significantly, it would explain the Apoptin fibrils observed in the cytoplasm but not the 
nucleus under immunofluoresense. GFP fused to the N-terminus of Apoptin are known to instead form 
punctate aggregates in the cytosol, possibly a consequence of GFP interfering with the stability of large 
stacks of the extended peptides. The amyloid-like formation would also explain the fact that the 
appearance of Apoptin foci only occurs after a certain period of time and are only observed in the 
cytoplasm. Nelson et al. proposed that the rate limiting step in amyloid formation is the nucleation step, 
which requires high protein levels to occur ( 29). Only after a certain period of time would Apoptin’s 
concentration be high enough for productive nucleation. Additionally, active export from the nucleus 
would reduce Apoptin’s concentration below the threshold needed for nucleation. This mechanism is in 
contrast to the possibility that Apoptin associates with existing fibrils in the cytosol, like actin filiments, 
which are present in the cytoplasm but not the nucleus. If Apoptin did associate directly with existing 
filiments, it would not explain the time it takes for Apoptin foci to form. An immunofluorscence time-
course assay would be useful to distinguish the two possibilities. If Apoptin filaments are found from the 
beginning of expression, when Apoptin’s concentration is low, then Apoptin most likely associates with 
existing cytosolic filaments. However if the filaments only appear after a certain amount of time, it 
would point to an amyloid-like Apoptin filament. Most significantly though, the possibility that an 
extended peptide could pull double duty in both the NES and multimerization domains could explain 
why mutations in the NES also disrupt multimerization. A mutation in one of the hydrophobic residues 
needed for CRM1 binding could also destabilize the interactions between the extended peptides 
forming the amyloid-like fiber. However, given the preliminary data at this point, it is difficult to 
rationalize a structural basis as to why some mutations (ApI37A and ApI40A) eliminate nuclear export 
and not mutlimerization, while other mutations (ApL44AL46A) eliminate both nuclear export and 
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multimerization. While it is certain that each hydrophobic residues contributes differently to nuclear 
export or multimerization, at this point we are unable to say why each residues contributes differently. 
Perhaps the mutation of certain hydrophic resides disrupts the secondary strucuture, leading to loss of 
both export and multimerization, while other mutations only remove the residues needed for CRM1 
binding, while leaving the secondary structure unchanged. 
 Having the multimerizaton domain overlap with the NES domain could potentially result in an 
antagonistic relationship between multimerization and nuclear export if the NES is buried in the 
aggregated state. This is similar to the functioning on p53’s NES, which is buried in the protein-protein 
interface in the tetramer state. However a series of experiments have provided convincing evidence that 
Apoptin can shuttle between the nucleus and cytoplasm in at least a dimerized state, and potentially as 
larger aggregates. In the study, two differentially labeled mutant Apoptins were created which either 
lacked a functional NLS (GFP-Ap-pmNLS) or lacked a functional NES (dsRED-Ap-pmNES) (Heilman et al., 
2006). As expected, GFP-Ap-pmNLS always localized to the nucleus and dsRED-Ap-pmNES always 
localized to the cytoplasm, regardless if they were expressed in cancerous (H1299) or primary (PFF) cells. 
However coexpression of the mutants resulted in wild type localization patterns, partitioning into the 
nucleus of cancer cells and partitioning into the cytoplasm of primary cells. Restoration of wild type 
partitioning is presumably due to a functional NES and NLS being brought together by Apoptin 
dimerizing or multimerizing. As stated above, mutlimerization of p53’s would sandwhich the NES, 
masking its activity. Apoptin could not multimerize this way if its mutlimerization and NES map to the 
same residues. However if Apoptin multimerized similarly to amyloid fibers, a functional NES would be 
left exposed at the end of the stack, allowing for nuclear export of Apoptin aggregates. 
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Conclusions and Future Recommendations 
Apoptin, a viral protein from the chicken anemia virus, has the unique ability to selectively 
induce apoptosis in transformed cells but not primary cells. Apoptin contains both an NLS and NES, 
which promote the nucleocytoplasmic shuttling which is necessary to induce apoptosis. Overlapping the 
NES is the multimerization domain, which facilitates Apoptin’s aggregation into large, insoluble 
multimers. Because protein multimerization has the obvious potential of masking an NES, and because 
previous studies have shown that Apoptin can shuttle at least as a dimer, the question arose as to 
weather multimerization and nuclear export were functionally linked. All previous attempts to uncouple 
multimerization from nuclear export using site directed mutagenesis have failed. However this study has 
shown that mutlimerization and nuclear export can be uncoupled. Mutations I37A and I40A retain 
multimerization while loosing nuclear export.an obvious way of regulating NES activity via mas 
It will be necessary in the future to test each of the mutants for their ability to induce apoptosis 
in transformed cell lines such as H1299 cells, especially with the Apoptin mutants I37A and I40A. 
Previous studies have shown that chemical inhibition of nuclear export nullifies Apoptin mediated 
apoptosis. Therefore, it would be expected that ApI37A will show no apoptotic activity and that ApI40A 
will show cell to cell variability in apoptosis, mirroring its cell to cell variability in nuclear export. It will 
also be necessary to assess the ability for each of the Apoptin mutants that retained nuclear export 
(T43A, L44A, L46A) to induce apoptosis to verify that these mutations do not affect Apoptin’s ability to 
induce apoptosis even though nuclear export is functional.  
Although this study mutated many of the hydrophobic residues in Apoptin’s NES, several remain 
to be mutated. To assess the ability of additional hydrophobic residues of Apoptin’s NES to interact with 
CRM1, mutants ApI33A, ApI35A, ApI42A should be generated. Additionally double mutants ApI40AI42A 
and ApI33AI35A could be generated to see if those amino acids interact with CRM1 like L44 and L46 
appear to do. If double mutants ApI40AI42A and ApI33AI35A act like L44 and L46, then they should both 
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loose NES and multimerization activity, while their single mutants (ApI33A, ApI35A, ApI40A, ApI42A) 
should retain NES and multimerization (except ApI40A which has partial NES activity as verified by this 
study). In these regions of the NES, perhaps both hydrophobic residues are positioned similarly and so 
only one is needed to interact with CRM1. These same single and double mutants would also be useful 
to try to distinguish the exact domain for multimerization and to try to determine which amino acids are 
required for the multimerization interface. Is it possible to knock out multimerization with single 
mutants to disrupt the multimerization interface, or are double mutants required to so (perhaps by 
disrupting the secondary structure and disrupting the multimerization interface then)? 
Apoptin mutants that eliminate nuclear export while retaining multimerization will be 
indispensible in future studies of Apoptin’s mechanism of action. However, equally valuable would be 
mutants that retain nuclear export but lack multimerization. Potentially, mutations I33A and I35A could 
accomplish this. Residues I33 and I35 lie just upstream of the canonical NES but still within the predicted 
extended peptide. If Apoptin does form multimers similar to amalyoid fibrils, mutations I33 or I35 could 
disrupt the interactions between the extended peptides, without necessarily changing the position of 
the conserved hydrophobic residues in the downstream NES. 
Apoptin’s cancer killing ability, once revealed, could be utilized as a guide to future cancer 
therapy. Apoptin’s mechanism of action is particularly valuable since it is able to kill a broad spectrum of 
cancer cells in a novel p53-independent manner, while leaving most normal cells unharmed. It is 
significant that Apoptin kills via a p53 independent pathway, as roughly half of all cancers have a 
mutated p53 and are insensitive to therapies targeting this cellular policing pathway. If recapitulated in 
a cancer therapeutic, Apoptin’s broad yet specificity against cancer cells would be the holy grail of 
cancer treatment. The mutants generated in this study will aid in the future dissection of Apoptin’s 
mechanism of action and selectivity. If understood well enough, Apoptin research could provide a 
roadmap to designing new powerful, broadly acting anticancer therapeutics. 
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Figures 
 
Figure 1 – Nuclear import and export of the RAN-GTP cycle through the nuclear pore complex (NPC). (Key: NLS – Nuclear 
Localization Sequence. NES – Nuclear Export Sequence. Green proteins: Importin α and β, respectively. NPC – Nuclear Pore 
Complex.) ( 11) 
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Figure 2 – Regulation and effects of Cdk. Upon binding to the proper cyclin, the Cdk migrates to the nucleus where it 
phosphorylates the tails of histones surrounding particular genes. The DNA unwinds, allowing transcriptional machinery 
access to the gene. Once expressed, the gene products promote the next phase of the cell cycle. Green arrows represent 
activation, red blunt arrows represent inhibition, and black arrows represent physical associations or movement. 
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Figure 3 – The p53/Mdm2 anticancer pathway. Mdm2 normally antagonizes p53 through ubiquitylation. This process is 
blocked if kinases (e.g. ATM or Chk2) phosphorylate p53 or if Mdm2 is inhibited by antiproliferitive pathways (e.g. RAS). p53 
promotes expression of CKIs, which arrest the cell cycle and can eventually induce apoptosis. Green arrows represent 
activation, red blunt arrows represent inhibition, and black arrows represent physical associations or movement ( 17). 
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Figure 4 – Structural arrangement of the subunits of the APC/C as proposed by Thornton et al. ( 20). 
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Figure 5 – Extrinsic and intrinsic apoptotic pathways. Green arrows denote activation, while black arrows denote physical 
associations or translocations ( 22). 
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Figure 6 – NES Alignments. (A) The NES of Apoptin is shown aligned with other known canonical NES to illustrate conserved 
residues. (B) A graphic representation of each mutation induced in the canonical NES of Apoptin. The NES is located at the N-
terminus of Apoptin while the bipartile NLS is located at the C-terminus of Apoptin. (C) Sequencing results of mutants 
pGBKT7-ApI40A, pGBKT7-ApT43A, pGBKT7-ApL44A, and pGBKT7-ApL46A show successful mutations when compared to WT 
Apoptin. ApI40A was mutated from ATT to GCT, ApT43A was mutated from ACT to GCC, ApL44A was mutated from CTA to 
GCA and ApL46A was mutated from CTG to GCC. All of the mutations code for alanine. Note: Each megaprimer designed for 
the site-directed mutagenesis had all four the original bases changed to GCC; however, alanine is an amino acid whose 
wobble position of its codon can be any of the four bases so the fact that ApI40A and ApL44A did not take at the wobble 
position does not matter.  
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Figure 7 – Secondary structure predictions of NESs from Apoptin, SNUPN and p53. The top line is the amino acid sequence of 
each NES, aligned to the highly conserved C-terminal hydrophobic residue. The two lines below each NES sequence are the 
secondary structure predictions from JPRED and SSPRO. For SNUPN and p53, JPRED and SSPRO predicted the correct 
secondary structure, as determined by crystallography or NMR, respectively ( 12,28). Key: E: Extended peptide, H: α helix, C/- 
: no prediction. 
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Figure 8 – All Apoptin mutants retain multimerization in a yeast 2-hybrid assay. (A) Y190 yeast were transformed with 
pACT2-ApWT/pGBKT7-ApWT (positive control, panel 1A), pACT2-no insert/pGBKT7-no insert (negative control, panel 1B), no 
plasmid (negative control, panel 2B), pACT2-ApWT/pGBKT7-ApI37A (panel 2A), pACT2-ApWT/pGBKT7-ApI40A (panel 3A), 
pACT2-ApWT/pGBKT7-T43A (panel 3B), pACT2-ApWT/pGBKT7-L44A (panel 4A) and pACT2-ApWT/pGBKT7-L46A (panel 4B). 
The yeast were lifted off the plates with 3mm Whatman paper, cracked open in liquid nitrogen, and soaked in X-gal for 20 
hours at 30° C. (B) A graphic representation of when protein-protein interaction occurs between ApWT and Ap mutant 
(and/or ApWT). When the two halves of the transcription factor (DBD and TAD) are brought into close proximity, they turn 
on the Gal4 promoter thereby transcribing lacZ and producing β-galactosidase. When given X-gal, its cleaved by Β-
galactosidase into galactose and a blue colony stain, 5-bromo-4-chloro-3-hydroxyindole. 
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Figure 9 – Subcellular localization of mutated Apoptin NES. Constructs used are Apoptin with mutated NESs and are 
truncated to lack the NLS, and are fused to the C-terminus of GFP. 
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Figure 10 – Comparison of hydrophobic residues in SNUPN and Apoptin NES. This figure illustrates the known hydrophobic 
residues (in red) of SNUPN’s NES that interact CRM1. Hydrophobic residues of Apoptin’s NES likely to interact with CRM are 
shown in blue. It seems plausible, based on this alignment, that perhaps I33 of Apoptin also could interact with CRM1 like 
M1 of SNUPN. 
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Figure 11 – Possible alternative secondary structures and multimerization mechanisms of Apoptin. (Left, top) Diagram of a 
canonical α-helix NES, like SNUPN, binding to CRM1 ( 12). (Left, bottom) Diagram showing how multimerization of α-helical 
NESs can mask them, as occurs during p53 tetramerization ( 28). (Right, top) Speculative Apoptin NES structure based on 
secondary structure prediction programs. (Right, bottom) Diagram showing how an extended peptide conformation of 
Apoptin’s NES could allow for both multimerizations and nuclear export, if it multimerizes similar to amyloid fibrils ( 29). 
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